Skip to main content

Table 1 14-3-3σ immunostaining in relation to clinicopathological variables

From: The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas

Variables

Total

Cytoplasm

Nucleus

Cytoplasm and nucleus

 

n

Low

High

(%)

p 1

Low

High

(%)

p 1

Low

High

(%)

p 1

Age

    

0.21

   

0.96

   

0.06

   25–69

121

39

82

(68)

 

49

72

(60)

 

38

83

(69)

 

   70–84

147

34

113

(77)

 

62

85

(58)

 

28

119

(81)

 

   85+

34

11

23

(68)

 

14

20

(59)

 

10

24

(71)

 

FIGO

    

0.26

   

0.49

   

0.08

   Ia

11

2

9

(82)

 

4

7

(64)

 

2

9

(82)

 

   Ib

37

16

21

(57)

 

19

18

(49)

 

16

21

(57)

 

   II

110

28

82

(75)

 

43

67

(61)

 

22

88

(80)

 

   III

121

32

89

(74)

 

46

75

(62)

 

30

91

(75)

 

   IV

19

5

14

(74)

 

10

9

(47)

 

5

14

(74)

 

   Not available

4

            

Lymph node metastasis

    

0.42

   

0.97

   

0.54

   None

137

41

96

(70)

 

55

82

(60)

 

36

101

(74)

 

   Unilateral

76

18

58

(76)

 

31

45

(59)

 

17

59

(78)

 

   Bilateral

34

12

22

(65)

 

13

21

(62)

 

11

23

(68)

 

   Not available

55

            

Tumour diameter (cm)

    

0.001

   

0.002

   

0.001

   0.3–2.5

92

34

58

(63)

 

50

42

(46)

 

33

59

(64)

 

   2.6–4.0

94

30

64

(68)

 

35

59

(63)

 

25

69

(73)

 

   4.1–20.0

100

14

86

(86)

 

30

70

(70)

 

12

88

(88)

 

   Not available

16

            

Tumor differentiation

    

0.09

   

0.10

   

0.08

   Well

76

27

49

(65)

 

39

37

(49)

 

25

51

(67)

 

   Moderate

154

43

111

(72)

 

61

93

(60)

 

39

115

(75)

 

   Poor

72

14

58

(81)

 

25

47

(65)

 

12

60

(83)

 

Depth of invasion (mm)

    

0.01

   

0.001

   

0.007

   0.0–4.0

80

32

48

(60)

 

45

35

(44)

 

30

50

(63)

 

   4.1–8.0

99

24

75

(76)

 

38

61

(62)

 

21

78

(79)

 

   8.1–40.0

112

24

88

(79)

 

34

78

(70)

 

21

91

(81)

 

   Not available

11

            

Infiltration of vessel

    

0.33

   

0.50

   

0.41

   No

233

67

166

(71)

 

99

134

(58)

 

61

172

(74)

 

   Yes

66

15

51

(77)

 

25

41

(62)

 

14

52

(79)

 

   Not available

3

            

p142

    

1.00

   

1.00

   

0.88

   Low (-)

135

98

37

(27)

 

46

89

(66)

 

84

51

(38)

 

   High (+)

77

56

21

(27)

 

26

51

(66)

 

49

28

(36)

 

   Not available

100

            

p162

    

0.63

   

0.88

   

0.15

   Low (< 5%)

148

40

108

(73)

 

51

97

(66)

 

37

111

(75)

 

   High (≥ 5%)

63

15

48

(76)

 

21

42

(67)

 

10

53

(84)

 

   Not available

91

            

p212

    

0.17

   

0.87

   

0.10

   Low (-)

122

36

86

(71)

 

42

80

(66)

 

32

90

(74)

 

   High (+)

90

19

71

(79)

 

30

60

(67)

 

15

75

(84)

 

   Not available

90

            

p272

    

0.18

   

0.56

   

0.19

   Low (< 50%)

164

39

125

(76)

 

54

110

(67)

 

33

131

(80)

 

   High (≥ 50%)

48

16

32

(67)

 

18

30

(63)

 

14

34

(71)

 

   Not available

90

            

p532

    

0.70

   

0.12

   

0.93

   Low (< 5%)

93

25

68

(73)

 

26

67

(72)

 

20

73

(79)

 

   High (≥ 5%)

118

29

89

(75)

 

45

73

(62)

 

26

92

(78)

 

   Not available

91

            

Cyclin A2

    

0.68

   

0.09

   

0.59

   Low (< 5%)

61

17

44

(72)

 

26

35

(57)

 

15

46

(75)

 

   High (≥ 5%)

151

38

113

(75)

 

46

105

(70)

 

32

119

(79)

 

   Not available

90

            

Cyclin D12

    

0.87

   

0.75

   

0.83

   Low (-)

156

40

116

(74)

 

52

104

(67)

 

34

122

(78)

 

   High (+)

56

15

41

(73)

 

20

36

(64)

 

13

43

(77)

 

   Not available

90

            

Cyclin D32

    

0.25

   

0.76

   

0.69

   Low (< 50%)

153

43

110

(72)

 

51

102

(67)

 

35

118

(77)

 

   High (≥ 50%)

59

12

47

(80)

 

21

38

(64)

 

12

47

(80)

 

   Not available

90

            

Cyclin E2

    

0.72

   

0.64

   

0.32

   Low (< 50%)

173

44

129

(75)

 

60

113

(65)

 

36

137

(79)

 

   High (≥ 50%)

39

11

28

(72)

 

12

27

(69)

 

11

28

(72)

 

   Not available

90

            

HPV2

    

0.87

   

0.47

   

0.98

   Low (-)

168

44

124

(74)

 

57

111

(66)

 

39

129

(77)

 

   High (+)

44

11

33

(75)

 

15

29

(66)

 

8

36

(82)

 

   Not available

90

            
  1. 1 Pearson chi-square 2 In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [2831].